A randomised study of male participants with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy with a luteinising releasing hormone releasing hormone analogue (LHRHA) treatment combined with the commencement of either 160mg daily Enzalutamide or conventional Non-steroidal anti-androgen (NSAA) to determine the effects of overall survival

Trial Profile

A randomised study of male participants with localised prostate cancer at high risk for recurrence deemed suitable for external beam radiation therapy with a luteinising releasing hormone releasing hormone analogue (LHRHA) treatment combined with the commencement of either 160mg daily Enzalutamide or conventional Non-steroidal anti-androgen (NSAA) to determine the effects of overall survival

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Dec 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms ANZUP ENZARAD; ENZARAD
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 According to trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology, 398 patients have been enrolled as of 1 Feb 2017.
    • 02 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top